Definition

A dendritic cell (DC)–based cancer vaccine in which the autologous, in vitro activated DCs are loaded with messenger RNA (mRNA) encoding neoantigens from the patient’s non-small cell lung cancer (NSCLC), with potential immunomodulating and antineoplastic activities. Upon administration of autologous mRNA–encoding NSCLC neoantigens DC vaccine, the mRNA gets expressed into neoantigens in cells and the neoantgens activate the immune system to induce robust neoantigen-specific T-cell responses against the NSCLCs expressing these neoantigens. The neoantigens are predicted from the patient-individual tumor’s mutanome.